Genenta Science S.p.A (GNTA) Other Non-Current Liabilities (2022 - 2024)
Genenta Science S.p.A (GNTA) posted Other Non-Current Liabilities of $1237.4 for Q4 2024, down 85.6% sequentially from $8594.6 in Q2 2024, and down 92.12% YoY from $15702.3 in Q1 2024.
Genenta Science S.p.A (GNTA) Other Non-Current Liabilities (2022 - 2024) Analysis & Trends
Genenta Science S.p.A has reported Other Non-Current Liabilities for 3 years, with the latest figure at $1237.4 in Q4 2024.
- Quarterly Other Non-Current Liabilities fell 92.12% year-over-year to $1237.4 in Q4 2024, while the trailing twelve-month figure through Dec 2024 was $1237.4 (down 92.12% YoY) and the FY2024 annual result came in at $1237.4, down 92.12% from the prior year.
- Other Non-Current Liabilities declined to $1237.4 in Q4 2024 per GNTA's latest filing, from $8594.6 in the prior quarter.
- Over five years, Other Non-Current Liabilities peaked at $34580.1 in Q2 2022 and troughed at $1237.4 in Q4 2024.
- A 3-year average of $18459.2 and a median of $19287.0 in 2023 frame the typical range for Other Non-Current Liabilities.
- The sharpest annual moves came in 2023 and 2024: Other Non-Current Liabilities sank 33.86% in 2023, then slumped 92.12% in 2024.
- Over 3 years, Other Non-Current Liabilities stood at $27769.1 in 2022, then plunged by 43.45% to $15702.3 in 2023, then plunged by 92.12% to $1237.4 in 2024.
- According to Business Quant data, Other Non-Current Liabilities over the past three periods registered $1237.4, $8594.6, and $15702.3 for Q4 2024, Q2 2024, and Q4 2023 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Genenta Science S.p.A | 25.03 Mn | -34.07 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 1,237.43 |
| Jun 30, 2024 | 8,594.64 |
| Dec 31, 2023 | 15,702.27 |
| Jun 30, 2023 | 22,871.77 |
| Dec 31, 2022 | 27,769.09 |
| Jun 30, 2022 | 34,580.11 |